Drug profile · INN
halobetasol propionate
BRYHALI
halobetasol propionate (BRYHALI) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — halobetasol propionate
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 15
- Programs
- 2
- Data quality
- 0.84
Quick answer
halobetasol propionate (BRYHALI) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 2020339710
GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF
granted -
US 2020239601
CROSSLINKED POLYMERIC NETWORK AND USE THEREOF
granted -
CA 2883399
REDUCTION AU MINIMUM DE DEPOTS LIPIDIQUES BIOLOGIQUES SUR DES LENTILLES DE CONTACT
granted -
CA 2881745
COMPOSITIONS OPHTALMIQUES CONTENANT DES ACIDES GRAS OMEGA -3
granted -
WO 2013169458
COMPOSITIONS PHARMACEUTIQUES ET MÉTHODES DE TRAITEMENT, DE CONTRÔLE, D'AMÉLIORATION, OU D'INVERSION DES TROUBLES DE LA KÉRATOCONJONCTIVITE SÈCHE
granted -
US 2013289070
Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines
granted -
WO 2013133980
DÉRIVÉS NITROXY DE STÉROÏDES DOUX
granted -
WO 2013126156
COMPOSÉS AGONISTES DE RÉCEPTEURS DE GLUCOCORTICOÏDES SÉLECTIFS DONNEURS D'OXYDE NITRIQUE ET COMPOSITIONS OPHTALMIQUES
granted -
CA 2864833
COMPOSITIONS OPHTALMIQUES COMPRENANT DES CIRES NATURELLES ALCOXYLEES
granted -
EP 2624836
BEPOTASTIN-ZUSAMMENSETZUNG
granted -
CA 2851492
COMPOSITIONS OPHTALMIQUES EN GEL
granted -
CA 2838876
COMPOSITIONS ET PROCEDES DE TRAITEMENT, DE SUPPRESSION, DE REDUCTION OU D'AMELIORATION D'UNE DOULEUR INFLAMMATOIRE
granted -
US 2012255544
BEPOTASTINE COMPOSITIONS
granted -
WO 2012039887
COMPOSITION ET MÉTHODE ACCÉLÉRANT LA CICATRISATION DES PLAIES
granted -
WO 2011162951
COMPOSITIONS ET PROCÉDÉS D'AMÉLIORATION DE LA RÉDUCTION D'UN MICRO-ORGANISME SPOROGÈNE
granted
Frequently asked questions
What is halobetasol propionate?
halobetasol propionate (BRYHALI) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for halobetasol propionate?
BRYHALI is a marketed brand name for halobetasol propionate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of halobetasol propionate?
halobetasol propionate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.